Monica Grover1, Laura K Bachrach2. 1. Department of Pediatrics, Division of Endocrinology, School of Medicine, Stanford University, Room H314, Stanford, CA, 94305, USA. 2. Department of Pediatrics, Division of Endocrinology, School of Medicine, Stanford University, Room H314, Stanford, CA, 94305, USA. lkbach@stanford.edu.
Abstract
PURPOSE OF REVIEW: Osteoporosis is an under-recognized complication of chronic illness in childhood. This review will summarize recent literature addressing the risk factors, evaluation, and treatment for early bone fragility. RECENT FINDINGS: Criteria for the diagnosis of pediatric osteoporosis include the presence of low trauma vertebral fractures alone or the combination of low bone mineral density and several long bone fractures. Monitoring for bone health may include screening for vertebral fractures that are common but often asymptomatic. Pharmacologic agents should be offered to those with fragility fractures especially when spontaneous recovery is unlikely. Controversies persist about the optimal bisphosphonate agent, dose, and duration. Newer osteoporosis drugs have not yet been adequately tested in pediatrics, though clinical trials are underway. The prevalence of osteoporosis is increased in children with chronic illness. To reduce the frequency of fragility fractures requires increased attention to risk factors, early intervention, and additional research to optimize therapy and potentially prevent their occurrence.
PURPOSE OF REVIEW: Osteoporosis is an under-recognized complication of chronic illness in childhood. This review will summarize recent literature addressing the risk factors, evaluation, and treatment for early bone fragility. RECENT FINDINGS: Criteria for the diagnosis of pediatric osteoporosis include the presence of low trauma vertebral fractures alone or the combination of low bone mineral density and several long bone fractures. Monitoring for bone health may include screening for vertebral fractures that are common but often asymptomatic. Pharmacologic agents should be offered to those with fragility fractures especially when spontaneous recovery is unlikely. Controversies persist about the optimal bisphosphonate agent, dose, and duration. Newer osteoporosis drugs have not yet been adequately tested in pediatrics, though clinical trials are underway. The prevalence of osteoporosis is increased in children with chronic illness. To reduce the frequency of fragility fractures requires increased attention to risk factors, early intervention, and additional research to optimize therapy and potentially prevent their occurrence.
Entities:
Keywords:
Bisphosphonates; Bone fragility; Pediatric osteoporosis; Secondary osteoporosis; Vertebral fractures
Authors: Inari S Tamminen; Helena Valta; Hannu Jalanko; Sari Salminen; Mervi K Mäyränpää; Hanna Isaksson; Heikki Kröger; Outi Mäkitie Journal: Pediatr Nephrol Date: 2014-02-23 Impact factor: 3.714
Authors: C M Weaver; C M Gordon; K F Janz; H J Kalkwarf; J M Lappe; R Lewis; M O'Karma; T C Wallace; B S Zemel Journal: Osteoporos Int Date: 2016-02-08 Impact factor: 4.507
Authors: Lindsay M Griffin; Meena Thayu; Robert N Baldassano; Mark D DeBoer; Babette S Zemel; Michelle R Denburg; Lee A Denson; Justine Shults; Rita Herskovitz; Jin Long; Mary B Leonard Journal: J Clin Endocrinol Metab Date: 2015-04-28 Impact factor: 5.958
Authors: Jacqueline Halton; Isabelle Gaboury; Ronald Grant; Nathalie Alos; Elizabeth A Cummings; Maryann Matzinger; Nazih Shenouda; Brian Lentle; Sharon Abish; Stephanie Atkinson; Elizabeth Cairney; David Dix; Sara Israels; David Stephure; Beverly Wilson; John Hay; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: J Bone Miner Res Date: 2009-07 Impact factor: 6.741
Authors: Babette S Zemel; Mary B Leonard; Andrea Kelly; Joan M Lappe; Vicente Gilsanz; Sharon Oberfield; Soroosh Mahboubi; John A Shepherd; Thomas N Hangartner; Margaret M Frederick; Karen K Winer; Heidi J Kalkwarf Journal: J Clin Endocrinol Metab Date: 2010-01-26 Impact factor: 5.958
Authors: Eunyoung Kim; Han Eol Cho; Ji Ho Jung; Jang Woo Lee; Won Ah Choi; Seong-Woong Kang Journal: Medicine (Baltimore) Date: 2018-10 Impact factor: 1.817